glucose, (beta-d)-isomer has been researched along with Kidney Failure in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JB; Chen, WY; Chou, CA; Huang, CC; Lee, CT; Lee, WC; Li, LC; Yang, JL | 1 |
| Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A | 1 |
| Boulton, DW; Greasley, PJ; Hallow, KM; Heerspink, HL; Helmlinger, G; Nieves, EH; Penland, RC; van Raalte, DH | 1 |
| Boulton, DW; Jo, H; Parkinson, J; Pilla Reddy, V; Tang, W | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Jabbour, S | 1 |
| Cutler, DL; Hickman, A; O'Gorman, M; Sahasrabudhe, V; Saur, D; Shi, H; Terra, SG; Zhou, Z | 1 |
| Cos, X; Gillani, S; Khunti, K; Kunutsor, SK; Seidu, S | 1 |
| Engel, SS; Kaufman, KD; Lam, RLH; Morgan, J; O'Neill, EA; Raji, A; Scott, R; Zimmer, Z | 1 |
| Broedl, UC; Halabi, A; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ | 1 |
| Scheen, AJ | 1 |
| Broedl, UC; Koiwai, K; Macha, S; Sakamoto, W; Salsali, A; Sarashina, A; Sasaki, T; Tanaka, Y; Ueki, K; Woerle, HJ | 1 |
| Furihata, K; Inagaki, N; Ishii, M; Kondo, K; Kuki, H; Sakai, M; Yoshinari, T | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, W; Leeflang, S; Nakajo, I; Smulders, R; Taniuchi, Y; Zhang, W | 1 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
| Chen, J; He, P; Jiang, L; Liu, S; Liu, Y; Tan, N | 1 |
| Khandelwal, S; Naing, S; Poliyedath, A; Sigala, T | 1 |
| Li, D; Li, Y; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
6 review(s) available for glucose, (beta-d)-isomer and Kidney Failure
| Article | Year |
|---|---|
Durability of response to dapagliflozin: a review of long-term efficacy and safety.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Topics: Adult; Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United Kingdom | 2018 |
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Glucosides; Hepatic Insufficiency; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Impact of EMPA-REG OUTCOME
Topics: Benzhydryl Compounds; Body Weights and Measures; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Primary Health Care; Randomized Controlled Trials as Topic; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Renal Insufficiency; Reproducibility of Results; Risk; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
6 trial(s) available for glucose, (beta-d)-isomer and Kidney Failure
| Article | Year |
|---|---|
Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
Topics: Administration, Oral; Adolescent; Antibiotics, Antitubercular; Area Under Curve; Benzhydryl Compounds; Child; Child, Preschool; Computer Simulation; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Glucosides; Glucuronosyltransferase; Healthy Volunteers; Hepatic Insufficiency; Humans; Infant; Infant, Newborn; Male; Mefenamic Acid; Models, Biological; Predictive Value of Tests; Renal Insufficiency; Rifampin; Sodium-Glucose Transporter 2 Inhibitors; UDP-Glucuronosyltransferase 1A9 | 2021 |
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2 | 2017 |
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Least-Squares Analysis; Male; Middle Aged; Postprandial Period; Renal Insufficiency; Sitagliptin Phosphate; Treatment Outcome | 2018 |
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Topics: Adult; Aged; Area Under Curve; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Schedule; Fasting; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.
Topics: Adult; Aged; Area Under Curve; Asian People; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Thiophenes | 2014 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
7 other study(ies) available for glucose, (beta-d)-isomer and Kidney Failure
| Article | Year |
|---|---|
Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARĪ³/CD36 Pathway in Obese Mice.
Topics: Animals; Benzhydryl Compounds; CD36 Antigens; Cell Line, Transformed; Cell Survival; Diet, High-Fat; Fatty Acids, Nonesterified; Glucosides; Humans; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Palmitic Acid; PPAR gamma; Protective Agents; Renal Insufficiency; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2020 |
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
Topics: Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Models, Biological; Randomized Controlled Trials as Topic; Renal Insufficiency; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Resistance; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Male; Membrane Transport Modulators; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency; Renin-Angiotensin System; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Geraniin ameliorates cisplatin-induced nephrotoxicity in mice.
Topics: Animals; Cisplatin; Disease Models, Animal; Glucosides; Hydrolyzable Tannins; Kidney; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Renal Insufficiency | 2016 |